Literature DB >> 27168169

Refining the classification of left ventricular hypertrophy to provide new insights into the progression from hypertension to heart failure.

Sonia Garg1, Mark H Drazner.   

Abstract

PURPOSE OF REVIEW: Left ventricular hypertrophy (LVH), an important consequence of hypertension, is traditionally classified as either concentric or eccentric based on the presence or absence of increased relative wall thickness. In 2010, we proposed a novel four-tiered classification that accounted for LV dilatation in addition to LV wall thickness. The purpose of this review is to discuss the rationale for this revised classification and highlight subsequent studies that have assessed its utility. RECENT
FINDINGS: A series of recent observational studies have tested whether the four-tiered classification identifies subphenotypes of LVH with differential risk of adverse outcomes, including incident heart failure. The majority have confirmed that eccentric hypertrophy can be subdivided into a high-risk and a low-risk group based on whether LV dilatation is present. Additional studies have shown that LV dilatation is an independent risk factor for the development of heart failure.
SUMMARY: Incorporation of LV dilatation into the assessment of LVH identifies important subphenotypes within the standard two-tiered classification that have differential risk. Such refinements in the classification of LVH may yield new insights into how LVH progresses to heart failure, help identify risk factors for this transition, and improve therapeutic efforts to prevent its occurrence.

Entities:  

Mesh:

Year:  2016        PMID: 27168169     DOI: 10.1097/HCO.0000000000000299

Source DB:  PubMed          Journal:  Curr Opin Cardiol        ISSN: 0268-4705            Impact factor:   2.161


  7 in total

1.  Myocardial recovery after cardiac resynchronization therapy in left bundle branch block-associated idiopathic nonischemic cardiomyopathy: A NEOLITH II substudy.

Authors:  Norman C Wang; Aliza Hussain; Evan C Adelstein; Andrew D Althouse; Michael S Sharbaugh; Sandeep K Jain; Alaa A Shalaby; Andrew H Voigt; Samir Saba
Journal:  Ann Noninvasive Electrocardiol       Date:  2018-09-28       Impact factor: 1.468

Review 2.  Clinical Value of Complex Echocardiographic Left Ventricular Hypertrophy Classification Based on Concentricity, Mass, and Volume Quantification.

Authors:  Andrea Barbieri; Alessandro Albini; Anna Maisano; Gerardo De Mitri; Giovanni Camaioni; Niccolò Bonini; Francesca Mantovani; Giuseppe Boriani
Journal:  Front Cardiovasc Med       Date:  2021-04-27

Review 3.  The CXCL10/CXCR3 Axis and Cardiac Inflammation: Implications for Immunotherapy to Treat Infectious and Noninfectious Diseases of the Heart.

Authors:  Raffaele Altara; Ziad Mallat; George W Booz; Fouad A Zouein
Journal:  J Immunol Res       Date:  2016-10-03       Impact factor: 4.818

Review 4.  Multimodality Imaging for Left Ventricular Hypertrophy Severity Grading: A Methodological Review.

Authors:  Maaike Alkema; Ernest Spitzer; Osama I I Soliman; Christian Loewe
Journal:  J Cardiovasc Ultrasound       Date:  2016-12-28

5.  Edaravone inhibits pressure overload-induced cardiac fibrosis and dysfunction by reducing expression of angiotensin II AT1 receptor.

Authors:  Wei-Wei Zhang; Feng Bai; Jin Wang; Rong-Hua Zheng; Li-Wang Yang; Erskine A James; Zhi-Qing Zhao
Journal:  Drug Des Devel Ther       Date:  2017-10-16       Impact factor: 4.162

6.  Correlation between adolescent chronic emotional stress and incidence of adult cardiovascular disease in female rats.

Authors:  Monireh-Sadat Mousavi; Alireza Imani; Sogol Meknatkhah; Gholamhossein Riazi
Journal:  Iran J Basic Med Sci       Date:  2019-10       Impact factor: 2.699

7.  An essential role for Wnt/β-catenin signaling in mediating hypertensive heart disease.

Authors:  Yue Zhao; Chunhong Wang; Cong Wang; Xue Hong; Jinhua Miao; Yulin Liao; Lili Zhou; Youhua Liu
Journal:  Sci Rep       Date:  2018-06-12       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.